CD274 and triple-negative breast carcinoma: The latter aims to evaluate the potential interest of an anti-PDL1 antibody called MPDL3280A labelled with 89Zr for non-invasive imaging and quantification of PD-L1 distribution in patients with locally advanced or metastatic non-small cell lung cancer, bladder cancer or triple-negative breast cancer.